Burkitt lymphoma in a scalp region: a case report of it's recurrence in a 13-year-old child
- PMID: 38846844
- PMCID: PMC11152782
- DOI: 10.1097/MS9.0000000000002089
Burkitt lymphoma in a scalp region: a case report of it's recurrence in a 13-year-old child
Abstract
Introduction: Burkitt lymphoma (BL) is an aggressive non-Hodgkin lymphoma characterized by chromosome 8 MYC gene translocation. It manifests in three clinical types: immunodeficiency-related, sporadic (nonendemic), and endemic (African), each differing in epidemiology and clinical behavior. Treatment typically involves enrollment in clinical trials or intensive chemotherapy regimens like R-CODOX-M/IVAC. The authors present a case of recurrent BL following treatment.
Case report: A 13-year-old female presented with a gradually progressive swelling in the left parieto-occipital region. Examination revealed normal vital signs and a Glasgow coma scale, with seronegative findings on investigations. An excision of a subganglion soft tissue tumor was performed, revealing histopathological features suggestive of a small round blue cell tumor. After chemotherapy, the patient experienced a recurrence in the scalp region, diagnosed as BL.
Discussion: While scarce reports exist on BL in the scalp region, cases have been documented in various body locations. Treatment strategies, including chemotherapy and surgery, have shown promising results in managing the disease and improving symptoms.
Conclusion: The recurrence of BL is rare, highlighting the importance of vigilance in monitoring patients post-treatment. The authors report a case of recurrent BL in a 13-year-old female, emphasizing the need for continued research and surveillance in managing this aggressive malignancy.
Keywords: burkitt lymphoma; non-hodgkin lymphoma; recurrence.
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
The author declares no conflicts of interest.Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
Figures
Similar articles
-
Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.Cancer. 2003 Sep 15;98(6):1196-205. doi: 10.1002/cncr.11628. Cancer. 2003. PMID: 12973843
-
Burkitt leukaemia/lymphoma: R-CODOX-M/R-IVAC remains gold standard treatment in BL.Ir J Med Sci. 2016 Nov;185(4):773-777. doi: 10.1007/s11845-015-1288-3. Epub 2015 Apr 7. Ir J Med Sci. 2016. PMID: 25843016
-
Chemotherapy Treatments for Burkitt Lymphoma: Systematic Review of Interventional Studies.Clin Lymphoma Myeloma Leuk. 2021 Aug;21(8):514-525. doi: 10.1016/j.clml.2021.03.012. Epub 2021 Apr 3. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33947633
-
Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL.Int J Hematol. 2010 Dec;92(5):732-43. doi: 10.1007/s12185-010-0728-0. Epub 2010 Dec 1. Int J Hematol. 2010. PMID: 21120644
-
Burkitt lymphoma- a rare but challenging lymphoma.Best Pract Res Clin Haematol. 2018 Sep;31(3):279-284. doi: 10.1016/j.beha.2018.07.013. Epub 2018 Jul 23. Best Pract Res Clin Haematol. 2018. PMID: 30213397 Review.
References
-
- UpToDate www.uptodate.com . Accessed 01, March 2023. https://www.uptodate.com/contents/epidemiology-clinical-manifestations-p...
-
- Magrath I. Epidemiology: clues to the pathogenesis of Burkitt lymphoma. Br J Haematol 2012;156:744–756. - PubMed
Publication types
LinkOut - more resources
Full Text Sources